-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RXeVdirvBg32Qk2hcQUqAkudFN3KPU0inJVFKXL92SI1L1sq+XVgiLgl0b4whnYL XgRnEqfzCWMCyInZrTm3Kg== 0000950162-02-000384.txt : 20020415 0000950162-02-000384.hdr.sgml : 20020415 ACCESSION NUMBER: 0000950162-02-000384 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020312 GROUP MEMBERS: DEFIANTE FARMACEUTICA UNIPOSSOAL, L.D.A. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: REGENERX BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0000707511 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521253406 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-37837 FILM NUMBER: 02573581 BUSINESS ADDRESS: STREET 1: 3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: 3019611992 MAIL ADDRESS: STREET 1: 3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 FORMER COMPANY: FORMER CONFORMED NAME: ALPHA 1 BIOMEDICALS INC DATE OF NAME CHANGE: 19950719 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: SIGMA TAU FINANZIARIA CENTRAL INDEX KEY: 0001092601 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: VIA SUDAFRICA 20 STREET 2: 00144 CITY: ROME ITALY MAIL ADDRESS: STREET 1: VIA SUDAFRICA 20 STREET 2: 00144 CITY: ROME ITALY SC 13G 1 sigma13g031202.txt SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 RegeneRX Biopharmaceuticals, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, Par Value $0.001 per share - -------------------------------------------------------------------------------- (Title of Class of Securities) 020910105 - -------------------------------------------------------------------------------- (CUSIP Number) March 7, 2002 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: / / Rule 13d-1(b) /X/ Rule 13d-1(c) / / Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP 232808105 SCHEDULE 13G 2 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Sigma-Tau Finanziaria SpA - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) / / (b) / / - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Italy - -------------------------------------------------------------------------------- 5. Sole Voting Power 0 ---------------------------------------------------- Number of 6. Shared Voting Power Shares Beneficially 4,255,319 ---------------------------------------------------- Owned by Each 7. Sole Dispositive Power Reporting Person With: 0 - -------------------------------------------------------------------------------- 8. Shared Dispositive Power 4,255,319 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,255,319 - -------------------------------------------------------------------------------- 10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) / / - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 15.9% - -------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) CO CUSIP 232808105 SCHEDULE 13G 3 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Defiante Farmaceutica Unipessoal, L.d.a. - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) / / (b) / / - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Portugal - -------------------------------------------------------------------------------- 5. Sole Voting Power 0 ----------------------------------------------------- Number of 6. Shared Voting Power Shares Beneficially 4,255,319 ----------------------------------------------------- Owned by Each 7. Sole Dispositive Power Reporting Person With: 0 ----------------------------------------------------- 8. Shared Dispositive Power 4,255,319 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,255,319 - -------------------------------------------------------------------------------- 10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) / / - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 15.9% - -------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) CO CUSIP 232808105 SCHEDULE 13G 4 Item 1(a). Name of Issuer: RegeneRX Biopharmaceuticals, Inc. Item 1(b). Address of Issuer's Principal Executive Offices: 3 Bethesda, Metro Center Suite 700 Bethesda, MD 20814 Item 2(a). Name of Person Filing: This statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons") (1) Sigma-Tau Finanziaria SpA ("Sigma-Tau") (2) Defiante Farmaceutica Unipessoal, L.d.a., a wholly owned subsidiary of Sigma-Tau ("Defiante"). Item 2(b). Address of Principal Business Office: (1) Sigma-Tau Via Sudafrica, 20 00144 Rome Italy (2) Defiante Rua dos Ferreiros, 260 Funchal-Madeira (Portogallo) 9000-082 Item 2(c). Citizenship: (1) Sigma-Tau is an Italian corporation. (2) Defiante is a Portuguese corporation. Item 2(d). Title of Class of Securities: Common Stock, Par Value $0.001 per share (the "Shares") Item 2(e). CUSIP Number: 020910105 Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or 240.13d-2(b) or (c), check whether the person is a: This Item 3 is not applicable CUSIP 232808105 SCHEDULE 13G 5 Item 4. Ownership: (1) Sigma-Tau (a) Amount beneficially owned: 4,255,319(1) (b) Percent of class: 15.9% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 4,255,319 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 4,255,319 (2) Defiante (a) Amount beneficially owned: 4,255,319(1) (b) Percent of class: 15.9% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 4,255,319 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 4,255,319 --------- (1): All of the Shares are held by Defiante and are restricted shares subject to certain limitations on resale. Item 5. Ownership of Five Percent or Less of a Class: Not Applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company: Not Applicable Item 8. Identification and Classification of Members of the Group: Not Applicable Item 9. Notice of Dissolution of Group: Not Applicable CUSIP 232808105 SCHEDULE 13G 6 Item 10. Certification: By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: March 12, 2002 SIGMA TAU FINANZIARIA SPA By: /s/ Paolo Cavazza --------------------------------------------- Name: Paolo Cavazza Title: Vice President and Managing Director Defiante Farmaceutica Unipessoal, L.d.a. By: /s/ Antonio Nicolai --------------------------------------------- Name: Antonio Nicolai Title: Director CUSIP 232808105 SCHEDULE 13G 7 EXHIBIT INDEX Page No. A. Joint Filing Agreement dated March 12, 2002 by and among Sigma Tau Finanziaria SpA and Defiante Farmaceutica Unipessoal, L.d.a..................................................................8 CUSIP 232808105 SCHEDULE 13G 8 EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of RegeneRX Biopharmaceuticals, Inc. dated as of March 12, 2002 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(f) under the Securities Exchange Act of 1934. Dated: March 12, 2002 SIGMA TAU FINANZIARIA SPA By: /s/ Paolo Cavazza --------------------------------- Name: Paolo Cavazza Title: Vice President & Managing Director Defiante Farmaceutica Unipessoal, L.d.a. Dated: March 12, 2002 By: /s/ Antonio Nicolai --------------------------------- Name: Antonio Nicolai Title: Director -----END PRIVACY-ENHANCED MESSAGE-----